Brief: Gen Ilac Says It Receives Ethical Board Approval In The Netherlands For Phase 2 Trial Of Drug Candidate Sul-238
16/03/2026 11:21
March 16 (Reuters) - Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret GENIL.IS: GEN ILAC - RECEIVES ETHICAL BOARD APPROVAL IN NETHERLANDS FOR PHASE 2 TRIAL OF DRUG CANDIDATE SUL-238 Source text: nIKAb8XwHn Further company coverage: GENIL.IS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;; +48 58 7696600;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira